Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 7Specimen Handling 5fludarabine 4Standard of Care 4trametinib 3Practice Guidelines as Topic 3Magnetic Resonance Spectroscopy 3GSK2636771 3Biopsy 3venetoclax 2talquetamab 2osimertinib 2dabrafenib 2capivasertib 2binimetinib 2X-Rays 2Thiotepa 2Tacrolimus 2Patient Navigation 2Nivolumab 2Mycophenolic Acid 2Methods 2Mesna 2Melphalan 2Filgrastim 2Educational Status 2Early Intervention, Educational 2Crizotinib 2Ado-Trastuzumab Emtansine 22-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × brexucabtagene autoleucel × 30 days × Clear all
NCT05041309 2026-05-14

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Gilead Sciences

Enrolling by invitation
1,000 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡